A Phase 2 interventional study of LYS228 and Standard of care therapy in Complicated Urinary Tract Infections, sponsored by Novartis Pharmaceuticals. Withdrawn at 5 sites in 3 countries. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2018-10-26.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 2, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 274 studies in Urinary Tract Infections with a site in United States — 43 open to participants now, 56 under way, 2 of them phase 3. Urinary Tract Infections · United States.
Among the 274 studies in Urinary Tract Infections with a site in United States, this one is the 215th largest by enrollment of the 224 interventional ones that give a count, is one of 23 that started in 2018, is one of 31 in phase 2, and was the 141st registered.
807 studies on the registry are indexed under Urinary Tract Infections; 133 are open to participants now.
Browse Urinary Tract Infections studies →43 of the 274 studies in Urinary Tract Infections with a site in United States are open now. Recruiting first, the newest first:
GlaxoSmithKline · Sites in United States
Ages 15–50 · Women only
University of Miami · Sites in United States
Ages 18+ · Women only
GlaxoSmithKline · Sites in United States
Ages 18–50 · Women only · Healthy volunteers
Megan Bradley · Sites in United States
Ages 65+ · Women only
Baylor College of Medicine · Sites in United States
Ages 0 mo–5 mo · Men only
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 83 Urinary Tract Infections studies recruiting now, 50 (60%) set no upper age limit and 23 (28%) stop at 75 or younger; 16 take children under 18; 15 take healthy volunteers.
This study: 18 Years to 85 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
274 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 27 · Phase 2 41 · Phase 3 33 · Phase 4 39
First in 1988; this study’s year is marked. 23 started in 2018.
By drug class, each counting the studies that test any of its medicines:
Median enrollment 100 across the 224 interventional studies, 229 across the 50 observational. Of the 190 that completed or were terminated, 89 (47%) have results posted.
This tab as a report to print or save as PDF → With an account.
73 of 274 have an industry lead sponsor. The 10 most frequent:
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,721 studies on the registry; 222 are open to participants now.
Of its 586 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
Novartis has 1 study filed under Urinary Tract Infections — fewer than ten, so there is no comparison to draw.
26 of the studies in Urinary Tract Infections with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07686055Phase 3Megan BradleyPrecision Management of Urinary Tract Symptoms in Older Women | 2027-02-01 |
| NCT07947108Good Kitty CoA Clinical Trial to Evaluate the Effects of a Supplement on Urinary Symptoms | 2026-12 |
| NCT06976125University Hospitals Cleveland Medical CenterApplication of a Prediction Model for Directing Antibiotic Use in the Treatment of Urinary Tract Infection in an Ambulatory Setting | 2026-12-01 |
| NCT07453693Bonafide HealthAn Efficacy Study of a Dietary Supplement Drink Mix for Urinary Health Improvement | 2026-12-15 |
| NCT07542834Ohio UniversityUsing Virtual Reality to Improve Medical Training | 2026-12-31 |
Add all 26 to your calendar (.ics) → With an account.
Among the 274 studies in Urinary Tract Infections with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of the study is to evaluate whether LYS228 can be developed for the treatment of complicated urinary tract infections
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
IV infusion
Drug: LYS228
IV infusion of standard of care antibiotics for at least 5 days
Drug: Standard of care therapy
LYS228 IV infusion
IV infusion of standard of care antibiotics
Change from Baseline of the Clinical Response at Day 7
Clinical success at 7 days after randomization determined by signs and symptoms of infection and the need for additional antibiotics
Time frame: Baseline, Day 7
Plasma Pharmacokinetics (PK) of LYS228: Area Under the Plasma Concentration-time Curve from time zero to the end of dosing interval tau (AUCtau)
Calculated based on LYS228 concentration in blood at different time points following drug administration on Day 5
Time frame: Day 5
Plasma Pharmacokinetics (PK) of LYS228: The observed maximum plasma concentration following drug administration (Cmax)
Calculated based on LYS228 concentration in blood at different time points following drug administration on Day 5
Time frame: Day 5
Plasma Pharmacokinetics (PK) of LYS228: The time to reach the maximum concentration after drug administration (Tmax)
Calculated based on LYS228 concentration in blood at different time points following drug administration on Day 5
Time frame: Day 5
Plasma Pharmacokinetics (PK) of LYS228: The systemic (or total body) clearance from plasma following intravenous administration (CL)
Calculated based on LYS228 concentration in blood at different time points following drug administration on Day 5
Time frame: Day 5
Plasma Pharmacokinetics (PK) of LYS228: The volume of distribution at steady state following intravenous administration (Vss)
Calculated based on LYS228 concentration in blood at different time points following drug administration on Day 5
Time frame: Day 5
Plasma Pharmacokinetics (PK) of LYS228: The terminal elimination half-life (T 1/2)
Calculated based on LYS228 concentration in blood at different time points following drug administration on Day 5
Time frame: Day 5
Plasma Pharmacokinetics (PK) of LYS228: The amount of time in which the unbound drug concentration exceeds the minimum inhibitory concentration of the organism (%fT>MIC)
Calculated based on LYS228 concentration in blood at different time points following drug administration on Day 5
Time frame: Day 5
Urine Pharmacokinetics (PK) of LYS228: The amount of drug eliminated in Urine from 0 hours up to 6 hours following intravenus administration (Ae0-6h)
Calculated based on LYS228 concentration in urine at different time points following drug administration on Day 5
Time frame: Day 5
Urine Pharmacokinetics (PK) of LYS228: Renal Clearance (CLr)
Calculated based on LYS228 concentration in urine at different time points following drug administration on Day 5
Time frame: Day 5
Change from Baseline of the Microbiological Response at Day 7
Microbiologic success at 7 days after randomization determined by microbial growth in urine culture
Time frame: Baseline, Day 7
Plan to share: Undecided — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com
Start is estimated for Oct 2018; primary completion for Oct 2019, 12 months later.
How these figures are worked out, and which studies are left out of them.
This study is withdrawn, as verified in Oct 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.